Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity

Doxorubicin is a cytotoxic drug used for the treatment of many cancer types. However, its significant dose-related adverse effects including cardiotoxicity may hamper its efficiency. Moreover, the multidrug resistance that appears during treatments limits anti-cancer therapies. Hyperthermia has been...

Full description

Bibliographic Details
Main Authors: Darine El Hajj Diab, Pascal Clerc, Nizar Serhan, Daniel Fourmy, Véronique Gigoux
Format: Article
Language:English
Published: MDPI AG 2018-06-01
Series:Nanomaterials
Subjects:
Online Access:http://www.mdpi.com/2079-4991/8/7/468
id doaj-8fb0327444e3416a832ddef3b736c98a
record_format Article
spelling doaj-8fb0327444e3416a832ddef3b736c98a2020-11-24T23:11:30ZengMDPI AGNanomaterials2079-49912018-06-018746810.3390/nano8070468nano8070468Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral ActivityDarine El Hajj Diab0Pascal Clerc1Nizar Serhan2Daniel Fourmy3Véronique Gigoux4INSERM ERL1226—Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, FranceINSERM ERL1226—Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, FranceINSERM ERL1226—Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, FranceINSERM ERL1226—Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, FranceINSERM ERL1226—Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, FranceDoxorubicin is a cytotoxic drug used for the treatment of many cancer types. However, its significant dose-related adverse effects including cardiotoxicity may hamper its efficiency. Moreover, the multidrug resistance that appears during treatments limits anti-cancer therapies. Hyperthermia has been introduced as an adjuvant anti-cancer therapy and presents promising opportunities especially in combination with chemotherapy. However, hyperthermia methods including standard magnetic hyperthermia do not discriminate between the target and the surrounding normal tissues and can lead to side effects. In this context, a Magnetic Intra-Lysosomal Hyperthermia (MILH) approach, which occurs without perceptible temperature rise, has been developed. We previously showed that minute amounts of iron oxide magnetic nanoparticles targeting the gastrin receptor (CCK2R) are internalized by cancer cells through a CCK2R-dependent physiological process, accumulated into their lysosomes and kill cancer cells upon high frequency alternating magnetic field (AMF) application through lysosomal cell death. Here, we show that the combination of MILH with doxorubicin increases the efficiency of the eradication of endocrine tumor cells with synergism. We also demonstrate that these two treatments activate two different cell death pathways that are respectively dependent on Caspase-1 and Caspase-3 activation. These findings will result in the development of new anti-tumoral, intra-lysosomal-thermo/chemotherapy with better curative effects than chemotherapy alone and that are devoid of adverse effects linked to standard hyperthermia approaches.http://www.mdpi.com/2079-4991/8/7/468magnetic nanoparticlesmagnetic hyperthermiacell deathcancerendocrine tumorsdoxorubicin
collection DOAJ
language English
format Article
sources DOAJ
author Darine El Hajj Diab
Pascal Clerc
Nizar Serhan
Daniel Fourmy
Véronique Gigoux
spellingShingle Darine El Hajj Diab
Pascal Clerc
Nizar Serhan
Daniel Fourmy
Véronique Gigoux
Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity
Nanomaterials
magnetic nanoparticles
magnetic hyperthermia
cell death
cancer
endocrine tumors
doxorubicin
author_facet Darine El Hajj Diab
Pascal Clerc
Nizar Serhan
Daniel Fourmy
Véronique Gigoux
author_sort Darine El Hajj Diab
title Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity
title_short Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity
title_full Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity
title_fullStr Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity
title_full_unstemmed Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity
title_sort combined treatments of magnetic intra-lysosomal hyperthermia with doxorubicin promotes synergistic anti-tumoral activity
publisher MDPI AG
series Nanomaterials
issn 2079-4991
publishDate 2018-06-01
description Doxorubicin is a cytotoxic drug used for the treatment of many cancer types. However, its significant dose-related adverse effects including cardiotoxicity may hamper its efficiency. Moreover, the multidrug resistance that appears during treatments limits anti-cancer therapies. Hyperthermia has been introduced as an adjuvant anti-cancer therapy and presents promising opportunities especially in combination with chemotherapy. However, hyperthermia methods including standard magnetic hyperthermia do not discriminate between the target and the surrounding normal tissues and can lead to side effects. In this context, a Magnetic Intra-Lysosomal Hyperthermia (MILH) approach, which occurs without perceptible temperature rise, has been developed. We previously showed that minute amounts of iron oxide magnetic nanoparticles targeting the gastrin receptor (CCK2R) are internalized by cancer cells through a CCK2R-dependent physiological process, accumulated into their lysosomes and kill cancer cells upon high frequency alternating magnetic field (AMF) application through lysosomal cell death. Here, we show that the combination of MILH with doxorubicin increases the efficiency of the eradication of endocrine tumor cells with synergism. We also demonstrate that these two treatments activate two different cell death pathways that are respectively dependent on Caspase-1 and Caspase-3 activation. These findings will result in the development of new anti-tumoral, intra-lysosomal-thermo/chemotherapy with better curative effects than chemotherapy alone and that are devoid of adverse effects linked to standard hyperthermia approaches.
topic magnetic nanoparticles
magnetic hyperthermia
cell death
cancer
endocrine tumors
doxorubicin
url http://www.mdpi.com/2079-4991/8/7/468
work_keys_str_mv AT darineelhajjdiab combinedtreatmentsofmagneticintralysosomalhyperthermiawithdoxorubicinpromotessynergisticantitumoralactivity
AT pascalclerc combinedtreatmentsofmagneticintralysosomalhyperthermiawithdoxorubicinpromotessynergisticantitumoralactivity
AT nizarserhan combinedtreatmentsofmagneticintralysosomalhyperthermiawithdoxorubicinpromotessynergisticantitumoralactivity
AT danielfourmy combinedtreatmentsofmagneticintralysosomalhyperthermiawithdoxorubicinpromotessynergisticantitumoralactivity
AT veroniquegigoux combinedtreatmentsofmagneticintralysosomalhyperthermiawithdoxorubicinpromotessynergisticantitumoralactivity
_version_ 1725604091085717504